HGC019

HGC019

HGC019

Vaccine candidate against COVID-19

HGC019 is a mRNA and Self-amplifying mRNA (saRNA) based COVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Bio Corp. with active support from NIH under The Indo-US Vaccine Action Program (VAP) and Department of Biotechnology, India.[1]

Quick Facts Vaccine description, Target ...

Clinical trials

The phase-I trials began in February 2021 after receiving permission from Drugs Controller General of India (DGCI),[2][3] to evaluate the safety and immunogenicity of the vaccine candidate in about 120 participants consisting of age group (18–70) years.[4]

The phase-II trials is planned to conduct with 500 participants from the age group (18–75) years.[4] On 24 August 2021, the Drugs Controller General of India gave a go for phase II/III trials after it was found to be safe, tolerable, and immunogenic in the phase I trial results.[5][6][7]

Economics

The company has received a funding of ₹250 crore (around US$33.5 million) from Government of India based on the clinical trials progress.[8]

References

  1. [1]
    "mRNA Vaccines – HGC019". Gennova Biopharmaceuticals Limited. Retrieved 13 January 2021.
  2. [2]
    "Indigenous mRNA vaccine candidate supported by DBT gets Drug Controller nod to initiate Human clinical trials" (Press release). Press Information Bureau. Retrieved 13 January 2021.
  3. [3]
    Raghavan P (15 December 2020). "Pune-based Gennova to begin human trials of its Covid vaccine 'soon'". The Indian Express.
  4. [4]
    "Safety and immunogenicity study of mRNA based vaccine (HGCO19) against COVID-19 in healthy adult participants". ctri.nic.in. Clinical Trials Registry India. Retrieved 5 June 2021.
  5. [5]
    "DBT-BIRAC supported Nation's first mRNA-based vaccine found to be safe gets a nod from the Drugs Controller General of India DCG(I) to move into Phase II/III trial" (Press release). Press Information Bureau. Retrieved 25 August 2021.
  6. [6]
    "India's first mRNA vaccine found to be safe, given nod for Phase II/III trial". mint. 24 August 2021.
  7. [7]
    Singh S (24 August 2021). "India approves further trials for first homegrown mRNA COVID-19 shot". Reuters.
  8. [8]
    Geeta N (26 May 2021). "Trials of India's first mRNA Covid vaccine by Gennova on track". The Financial Express.
Scholia has a profile for HGC019 (Q106370223).


Stub icon

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article HGC019, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.